Neurotherapeutics

, Volume 4, Issue 1, pp 163–172

Vigabatrin

  • James W. Wheless
  • R. Eugene Ramsay
  • Stephen D. Collins
Article

Summary

Refractory epilepsies such as infantile spasms (IS) and complex partial seizures (CPS) can have a severe negative impact on the neurological integrity and quality of life of affected patients, in addition to drastically increasing their risk of premature mortality. Early identification of potentially effective pharmacotherapy agents is important. Vigabatrin has been shown to be a generally well tolerated and effective antiepileptic drug (AED) in a wide variety of seizure types affecting both children and adults, particularly those with IS and CPS. A bilateral, concentric constriction of the peripheral visual field characterizes the visual field defect (VFD) associated with vigabatrin, well characterized by numerous studies. This peripheral VFD presents in 30–50% of patients with exposure of several years; however, most of these patients are asymptomatic. In well-controlled studies, the earliest onset in patients with CPS is 11 months and at 5 months in infants, with average onsets being more than 5 years and 1 year, respectively. Patients with a peripheral VFD retain an average 65° of lateral vision (normal, 90°). The fact that many patients never develop the vigabatrin-related peripheral VFD, despite long-term exposure at high doses, may support the hypothesis that the injury is an idiosyncratic adverse drug reaction (as opposed to a strict dose- or duration-dependent toxicity). Effective testing methods are available to aid in the early detection and management of the peripheral VFD. This article discusses issues of importance to clinical decision-making in the use of vigabatrin to assist the physician and patient in assessing the benefits of vigabatrin therapy and understanding the potential risks of the VFD and uncontrolled seizures.

Key Words

vigabatrin epilepsy refractory epilepsy complex partial seizures infantile spasms West syndrome visual fields 

References

  1. 1.
    Beghi E. Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines. Lancet Neurol 2004;3: 618–621.PubMedGoogle Scholar
  2. 2.
    Berg AT, Shinnar S, Levy SR, Testa FM. Newly diagnosed epilepsy in children: presentation at diagnosis. Epilepsia 1999; 40: 445–452.PubMedGoogle Scholar
  3. 3.
    Forsgren L, Bucht G, Eriksson S, Bergmark L. Incidence and clinical characterization of unprovoked seizures in adults: a prospective population-based study. Epilepsia 1996;37: 224–229.PubMedGoogle Scholar
  4. 4.
    Murro AM. Complex partial seizures [Internet]. Updated: December 5, 2005. Accessed July 5, 2006. Available at http://www. emedicine.com/NEURO/topic74.htm.Google Scholar
  5. 5.
    Elterman RD, Shields WD, Mansfield KA, Nakagawa J; US Infantile Spasms Vigabatrin Study Group. Randomized trial of vigabatrin in patients with infantile spasms. Neurology 2001;57: 1416–1421.PubMedGoogle Scholar
  6. 6.
    Mackay MT, Weiss SK, Adams-Webber T, et al. Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. Neurology 2004;62: 1668–1681.PubMedGoogle Scholar
  7. 7.
    Nabbout R. A risk-benefit assessment of treatments for infantile spasms. Drug Saf 2001;24: 813–828.PubMedGoogle Scholar
  8. 8.
    Glauser TA. Following catastrophic epilepsy patients from childhood to adulthood. Epilepsia 2004;45(suppl 5): 23–26.PubMedGoogle Scholar
  9. 9.
    Riikonen R. Long-term outcome of patients with West syndrome. Brain Dev 2001;23: 683–687.PubMedGoogle Scholar
  10. 10.
    Product Information: Sabril, vigabatrin. Aventis Pharma Inc., Laval, Quebec, Canada.Google Scholar
  11. 11.
    Guberman A. Vigabatrin. Can J Neurol Sci 1996;23(4): S13-S17.PubMedGoogle Scholar
  12. 12.
    Rey E, Pons G, Richard MO, et al. Pharmacokinetics of the individual enantiomers of vigabatrin (gamma-vinyl GABA) in epileptic children. Br J Clin Pharmacol 1990;30: 253–257.PubMedGoogle Scholar
  13. 13.
    Rimmer EM, Richens A. Interaction between vigabatrin and phenytoin. Br J Clin Pharmacol 1989;27(suppl 1): 27S-33S.PubMedGoogle Scholar
  14. 14.
    Gatti G, Bartoli A, Marchiselli R, et al. Vigabatrin-induced decrease in serum phenytoin concentration does not involve a change in phenytoin bioavailability. Br J Clin Pharmacol 1993; 36: 603–606.PubMedGoogle Scholar
  15. 15.
    Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003;2: 347–356.PubMedGoogle Scholar
  16. 16.
    Garaizar C, Martinez-Gonzalez MJ, Fernández-Cuesta MA, et al. Seguimiento a Largo Plazo de la Epilepsia Infantil Tratada con vigabatrina, Fuere de los Ensayos Clinicos [Long-term follow-up of childhood epilepsy treated with vigabatrin outside of clinical trials. In Spanish]. Rev Neurol 1999;29: 201–207.PubMedGoogle Scholar
  17. 17.
    Chiron C, Dumas C, Jambaque I, Mumford J, Dulac O. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res 1997;26: 389–395.PubMedGoogle Scholar
  18. 18.
    Satishchandra P, Kashyap B, Goverdhan S, et al. Vigabatrin in intractable complex partial epilepsy. Epilepsia 1999;40(suppl 2): 256. Abstract.Google Scholar
  19. 19.
    Data on file. Ovation Pharmaceuticals. Protocol 717543C024.Google Scholar
  20. 20.
    Data on file. Ovation Pharmaceuticals. Protocol 71754 3 C 024.Google Scholar
  21. 21.
    Cramer JA, Fisher R, Ben-Menachem E, French J, Mattson RH. New antiepileptic drugs: comparison of key clinical trials. Epilepsia 1999;40: 590–600.PubMedGoogle Scholar
  22. 22.
    Coppola G. Treatment of partial seizures in childhood: an overview. CNS Drugs 2004;18: 133–156.PubMedGoogle Scholar
  23. 23.
    Luna D, Dulac O, Pajot N, Beaumont D. Vigabatrin in the treatment of childhood epilepsies: a single-blind placebo-controlled study. Epilepsia 1989;30: 430–437.PubMedGoogle Scholar
  24. 24.
    Dalla Bemardina B, Fontana E, Vigevano F, et al. Efficacy and tolerability of vigabatrin in children with refractory partial seizures: a single-blind dose-increasing study. Epilepsia 1995;36: 687–691.Google Scholar
  25. 25.
    Gobbi G, Pini A, Bertani G, et al. Prospective study of first-line vigabatrin monotherapy in childhood partial epilepsies. Epilepsy Res 1999;35: 29–37.PubMedGoogle Scholar
  26. 26.
    Zamponi N, Cardinali C. Open comparative long-term study of vigabatrin vs carbamazepine in newly diagnosed partial seizures in children. Arch Neurol 1999;56: 605–607.PubMedGoogle Scholar
  27. 27.
    Appleton RE, Peters AC, Mumford JP, Shaw DE. Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms. Epilepsia 1999;40: 1627–1633.PubMedGoogle Scholar
  28. 28.
    Chiron C, Dulac O, Beaumont D, Palacios L, Pajot N, Mumford J. Therapeutic trial of vigabatrin in refractory infantile spasms. J Child Neurol 1991;suppl 2:S52–S59.Google Scholar
  29. 29.
    Aicardi J, Mumford JP, Dumas C, Wood S; Sabril IS Investigator and Peer Review Groups. Vigabatrin as initial therapy for infantile spasms: a European retrospective survey. Epilepsia 1996;37: 638–642.PubMedGoogle Scholar
  30. 30.
    Mitchell WG, Shah NS. Vigabatrin for infantile spasms. Pediatr Neurol 2002;27: 161–164.PubMedGoogle Scholar
  31. 31.
    Vigevano F, Cilio MR. Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study. Epilepsia 1997;38: 1270–1274.PubMedGoogle Scholar
  32. 32.
    Lux AL, Edwards SW, Hancock E, et al. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. Lancet Neurol 2005; 4: 712–717.PubMedGoogle Scholar
  33. 33.
    Data on file. Ovation Pharmaceuticals. IND 47,707/Protocol 1A.Google Scholar
  34. 34.
    Elterman RD, Collins SD, Shields WD, Mansfield KA, Nakagawa J. Efficacy of vigabatrin in subjects with infantile spasms. Epilepsia 2005;46(suppl 8): 167.Abstract.Google Scholar
  35. 35.
    Appleton RE. Guideline may help in prescribing vigabatrin. BMJ 1998;317: 1322. Letter.PubMedGoogle Scholar
  36. 36.
    Frisen L, Malmgren K. Characterization of vigabatrin-associated optic atrophy. Acta Ophthalmol Scand 2003;81: 466–473.PubMedGoogle Scholar
  37. 37.
    Lux AL, Edwards SW, Osbome JP, et al. Revised guideline for prescribing vigabatrin in children: guideline’s claim about infantile spasms is not based on appropriate evidence. BMJ 2001;322: 236–237. Letter.PubMedGoogle Scholar
  38. 38.
    Vigabatrin Paediatric Advisory Group. Guideline for prescribing vigabatrin in children has been revised. BMJ 2000;320: 1404–1405.Google Scholar
  39. 39.
    Riikonen R. ACTH therapy of West syndrome: Finnish views. Brain Dev 2001;23: 642–646.PubMedGoogle Scholar
  40. 40.
    Paul SR, Krauss GL, Miller NR, Medura MT, Miller TA, Johnson MA. Visual function is stable in patients who continue long-term vigabatrin therapy: implications for clinical decision making. Epilepsia 2001;42: 525–530.PubMedGoogle Scholar
  41. 41.
    Wheless JW, Clarke DF, Carpenter D. Treatment of pediatric epilepsy: expert opinion, 2005. J Child Neurol 2005;20(suppl 1): S1-S56.PubMedGoogle Scholar
  42. 42.
    Spence SJ, Sankar R. Visual field defects and other ophthalmological disturbances associated with vigabatrin. Drug Saf 2001; 24: 385–404.PubMedGoogle Scholar
  43. 43.
    Guberman A, Bruni J; The Canadian Vigabatrin Study Group. Long-term open multicentre, add-on trial of vigabatrin in adult resistant partial epilepsy. Scizure 2000;9: 112–118.Google Scholar
  44. 44.
    Jambaque I, Chiron C, Dumas C, Mumford J, Dulac O. Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients. Epilepsy Res 2000;38: 151–160.PubMedGoogle Scholar
  45. 45.
    Sander JW, Hart YM, Trimble MR, Shorvon SD. Vigabatrin and psychosis. J Neurol Neurosurg Psychiatry 1991;54: 435–439.PubMedGoogle Scholar
  46. 46.
    Aldenkamp AP, Vermeulen J, Mulder OG, et al. Gamma-vinyl GABA (vigabatrin) and mood disturbances. Epilepsia 1994;35: 999–1004.PubMedGoogle Scholar
  47. 47.
    Wong IC. Retrospective study of vigabatrin and psychiatric behavioural disturbances. Epilepsy Res 1995;21: 227–230.PubMedGoogle Scholar
  48. 48.
    Thomas L, Trimble M, Schmitz B, Ring H. Vigabatrin and behaviour disorders: a retrospective survey. Epilepsy Res 1996;25: 21–27.PubMedGoogle Scholar
  49. 49.
    Kälviäinen R, Nousianen I, Mäntyjärvi M, et al. Initial vigabatrin monotherapy is associated with increased risk of visual field constriction: a comparative follow-up study with patients on initial carbamazepine monotherapy and healthy controls. Epilepsia 1998;39(suppl 6): 72. AbstractGoogle Scholar
  50. 50.
    Koehler J, Thömke F, Tettenborn B, et al. Influence of new antiepileptic drugs on visual evoked potentials. Epilepsia 1999; 40(suppl 2): 288. Abstract.Google Scholar
  51. 51.
    Sankar R, Wasterlain CG. Is the devil we know the lesser of two evils? Vigabatrin and visual fields Neurology 1999;52: 1537–1538. Comment.Google Scholar
  52. 52.
    Vanhatalo S, Paakkonen L, Nousiainen I. Visual field constriction in children treated with vigabatrin. Neurology 1999;52: 1713–1714.PubMedGoogle Scholar
  53. 53.
    Iannetti P, Spalice A, Perla FM, Conicella E, Raucci U, Bizzarri B. Visual field constriction in children with epilepsy on vigabatrin treatment. Pediatrics 2000;106: 838–842.PubMedGoogle Scholar
  54. 54.
    Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology 1998;50: 614–618.PubMedGoogle Scholar
  55. 55.
    Miller NR, Johnson MA, Paul SR, et al. Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings. Neurology 1999;53: 2082–2087.PubMedGoogle Scholar
  56. 56.
    Choi HJ, Kim DM. Visual field constriction associated with vigabatrin: retinal nerve fiber layer photographic correlation. J Neurol Neurosurg Psychiatry 2004;75: 1395.PubMedGoogle Scholar
  57. 57.
    Wild JM, Martinez C, Reinshagen G, Harding GF. Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 1999;40: 1784–1794.PubMedGoogle Scholar
  58. 58.
    Lawden MC, Eke T, Degg C, Harding GF, Wild JM. Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry 1999;67: 716–722.PubMedGoogle Scholar
  59. 59.
    Gross-Tsur V, Banin E, Shahar E, Shalev RS, Lahat E. Visual impairment in children with epilepsy treated with vigabatrin. Ann Neurol 2000;48: 60–64.PubMedGoogle Scholar
  60. 60.
    Lawden MC, Eke T, Degg C, et al. Visual field defects associated with vigabatrin treatment. Epilepsia 1999;40(suppl 2): 256. Abstract.Google Scholar
  61. 61.
    DeToledo JC, Westall CA, Collins SD. Vigabatrin induced visual fields defects: Update 2006. American Epilepsy Society Annual Meeting, December 1–5, 2006. Abstract 585 (poster).Google Scholar
  62. 62.
    Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997;314: 180–181.PubMedGoogle Scholar
  63. 63.
    Wong IC, Mawer GE, Sander JW. Severe persistent visual field constriction associated with vigabatrin: reaction might be dose dependent. BMJ 1997;314: 1693–1694. Comment.PubMedGoogle Scholar
  64. 64.
    Daneshvar H, Racette L, Coupland SG, Kertes PJ, Guberman A, Zackon D. Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology 1999;106: 1792–1798.PubMedGoogle Scholar
  65. 65.
    Buncic JR, Westall CA, Panton CM, Munn JR, MacKeen LD, Logan WJ. Characteristic retinal atrophy with secondary “inverse” optic atrophy identifies vigabatrin toxicity in children. Ophthalmology 2004; 111: 1935–1942.PubMedGoogle Scholar
  66. 66.
    Wild JM, Hope-Ross M, Harding GFA, Betts TA. Vigabatrin retinopathy. Invest Ophthalmol Vis Sci 2002 43:E-abstract 238.Google Scholar
  67. 67.
    Pelosse B, Momtchilova M, Roubergue A, Doummar D, Billette de Villemeur T, Laroche L. [Study of visual field and vigabatrin treatment in children]. In French. J Fr Ophtalmol 2001;24: 1075–1080.Google Scholar
  68. 68.
    Harding GF, Robertson K, Spencer EL, Holliday I. Vigabatrin: its effect on the electrophysiology of vision. Doc Ophthalmol 2002; 104: 213–229.PubMedGoogle Scholar
  69. 69.
    Harding GFA, Wild JM, Robertson K, et al. Electroculography, ERGs, multifocal ERGs and VEPs in epileptic patients showing visual field disorder. Electroencephalogr Clin Neurophysiol 1997; 103: 96. Abstract.Google Scholar
  70. 70.
    McDonagh J, Stephen LJ, Dolan FM, et al. Peripheral retinal dysfunction in patients taking vigabatrin. Neurology 2003;61: 1690–1694.PubMedGoogle Scholar
  71. 71.
    Morong S, Westall CA, Nobile R, et al. Longitudinal changes in photopic OPs occurring with vigabatrin treatment. Doc Ophthalmol 2003;107: 289–297.PubMedGoogle Scholar
  72. 72.
    Morong SE, Westall CA, Buncic RJ, Snead OC, Logan WJ, Weiss S. Sweep visual evoked potentials in infants with infantile spasms before and during vigabatrin treatment. Invest Ophthalmol Vis Sci 2003;43:E-abstract 2720.Google Scholar
  73. 73.
    Westall CA, Logan WJ, Smith K, Buncic JR, Panton CM, Abdolell M. The Hospital for Sick Children, Toronto, longitudinal ERG study of children on vigabatrin. Doc Ophthalmol 2002;104: 133–149.PubMedGoogle Scholar
  74. 74.
    Harding GF, Wild JM, Robertson KA, et al. Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction. Epilepsia 2000;41: 1420–1431.PubMedGoogle Scholar
  75. 75.
    Harding GF, Spencer EL, Wild JM, Conway M, Bohn RL. Field-specific visual-evoked potentials: identifying field defects in vigabatrin-treated children. Neurology 2002;58: 1261–1265.PubMedGoogle Scholar
  76. 76.
    Ruether K, Pung T, Kellner U, Schmitz B, Hartmann C, Seeliger M. Electrophysiologic evaluation of a patient with peripheral visual field contraction associated with vigabatrin. Arch Ophthalmol 1998;116: 817–819.PubMedGoogle Scholar
  77. 77.
    Hardus P, Verduin WM, Postma G, Stilma JS, Berendschot TT, van Veelen CW. Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication. Epilepsia 2000;41: 581–587.PubMedGoogle Scholar
  78. 78.
    Hardus P, Verduin WM, Postma G, Stilma JS, Berendschot TT, van Veelen CW. Long term changes in the visual fields of patients with temporal lobe epilepsy using vigabatrin. Br J Ophthalmol 2000;84: 788–790.PubMedGoogle Scholar
  79. 79.
    Gonzalez PA, McCall A, McQuistan A, Keating D, Brodie MJ, Parks S. Assessing retinal toxicity of vigabatrin and other GABA-ergic drugs in patients with epilepsy. Association for Research in Vision and Ophthalmology, 2005, 46, 1658:B521.Google Scholar
  80. 80.
    Gonzalez PA, Parks S, Kelly K, Brodie MJ. Progression of neuroretinal toxicity in patients on vigabatrin: objective assessment using the wide field multifocal electroretinogram. Epilepsia 2004; 45(suppl 7): 188. Abstract.Google Scholar
  81. 81.
    Nousiainen I, Kälviäinen R, Mäntyjärvi M. Contrast and glare sensitivity in epilepsy patients treated with vigabatrin or carbamazepine monotherapy compared with healthy volunteers. Br J Ophthalmol 2000;84: 622–625.PubMedGoogle Scholar
  82. 82.
    Nousiainen I, Kälviäinen R, Mäntyjärvi M. Color vision in epilepsy patients treated with vigabatrin or carbamazepine monotherapy. Ophthalmology 2000;107: 884–888.PubMedGoogle Scholar
  83. 83.
    Bayer A, Thiel HJ, Zrenner E, Paulus W, Ried S, Schmidt D. [Sensitive physiologic perceptual tests for ocular side effects of drugs exemplified by various anticonvulsants]. In German. Ophthalmologe 1995;92: 182–190.PubMedGoogle Scholar
  84. 84.
    Manuchehri K, Goodman S, Siviter L, Nightingale S. A controlled study of vigabatrin and visual abnormalities. Br J Ophthalmol 2000;84: 499–505.PubMedGoogle Scholar
  85. 85.
    Besch D, Safran AB, Kurtenbach A, et al. Visual field defects and inner retinal dysfunction associated with vigabatrin. Invest Ophthalmol Vis Sci 2000;41: 892S. Abstract 55.Google Scholar
  86. 86.
    Johnson MA, Krauss GL, Miller NR, Medura M, Paul SR. Visual function loss from vigabatrin: effect of stopping the drug. Neurology 2000;55: 40–45.PubMedGoogle Scholar
  87. 87.
    Kälviäinen R, Nousiainen I, Mäntyjärvi M, et al. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology 1999;53: 922–926.PubMedGoogle Scholar
  88. 88.
    Kälviäinen R, Nousiainen I, Mäntyjärvi M, et al. Prevalence of concentric visual field constriction in adult epilepsy patients with vigabatrin treatment. Neurology 1999;52(suppl 2): A235-A236. Abstract.Google Scholar
  89. 89.
    Gonzalez P, McCall A, McQuistan A, Keating D, Kelly K, Brodie MJ, Parks S. The assessment of neuro-retinal toxicity in patients with epilepsy on vigabatrin. Presented at: 42nd Annual Symposium, International Society of Clinical Electrophysiology in Vision, Glasgow, Scotland. August 22–26, 2005 (poster).Google Scholar
  90. 90.
    Wilson EA, Brodie MJ. Severe persistent visual field constriction associated with vigabatrin: chronic refractory epilepsy may have role in causing these unusual lesions. BMJ 1997;314: 1693. Comment.PubMedGoogle Scholar
  91. 91.
    Wohlrab G, Boltshauser E, Schmitt B, Schriever S, Landau K. Visual field constriction is not limited to children treated with vigabatrin. Neuropediatrics 1999;30: 130–132.PubMedGoogle Scholar
  92. 92.
    Arndt CF, Derambure P, Defoort-Dhellemmes S, Hache JC. Outer retinal dysfunction in patients treated with vigabatrin. Neurology 1999;52: 1201–1205.PubMedGoogle Scholar
  93. 93.
    Arndt CF, Derambure P, Defoort S, et al. Is visual impairment related to vigabatrin reversible? Epilepsia 1999;40(suppl 2): 256. Abstract.Google Scholar
  94. 94.
    Llerda MJ, Lasaosa SS, Juste TC, et al. Visual field defects associated with vigabatrin therapy: prevalence, characteristics and follow-up. Epilepsia 2000;41(suppl 7): 240. Abstract.Google Scholar
  95. 95.
    Toggweiler S, Wieser HG. Concentric visual field restriction under vigabatrin therapy: extent depends on the duration of drug intake. Scizure 2001;10: 420–423.Google Scholar
  96. 96.
    Specchio LM, Bellizzi M, La Neve A, et al. Visual impairment in adult epileptic patients treated with vigabatrin. Neurology 2000; 54(suppl 3): A308. Abstract.Google Scholar
  97. 97.
    Jensen H, Sjo O, Uldall P, Gram L. Vigabatrin and retinal changes. Doc Ophthalmol 2002;104: 171–180.PubMedGoogle Scholar
  98. 98.
    Rintahaka P, Granström ML, Lappi M, et al. Visual field defects in vigabatrin-treated children with epilepsy. Epilepsia 2000; 41(suppl 7): 196–197. Abstract.Google Scholar
  99. 99.
    Ascaso FJ, Lopez MJ, Mauri JA, Cristobal JA. Visual field defects in pediatric patients on vigabatrin monotherapy. Doc Ophthalmol 2003;107: 127–130.PubMedGoogle Scholar
  100. 100.
    Westall CA, Nobile R, Morong S, Buncic JR, Logan WJ, Panton CM. Changes in the electroretinogram resulting from discontinuation of vigabatrin in children. Doc Ophthalmol 2003;107: 299–309.PubMedGoogle Scholar
  101. 101.
    Westall CA, Nobile R, Buncic JR, Abdolell M. Electroretinogram indicators of toxicity in children taking the anti epileptic medication vigabatrin. Invest Ophthalmol Vis Sci 2005;46:E-Abstract 102.Google Scholar
  102. 102.
    Westall C. Visual electrophysiology to detect drug induced ocular toxicity: are abnormal results suggestive of toxicity? Presented at: 42nd Annual Symposium, International Society for Clinical Electrophysiology of Vision, Glasgow, Scotland, August 22–26, 2005 (oral presentation).Google Scholar
  103. 103.
    Westall CA, Nobile R, Buncic JR. Which factors contribute to worsening of ERGs in children taking the anti-epileptic drug vigabatrin? Invest Ophthalmol Vis Sci 2006;45:E-Abstract 775.Google Scholar
  104. 104.
    Hammoudi DS, Lee SSF, Madison A, et al. Reduced visual function associated with infantile spasms in children on vigabatrin therapy. Invest Ophthalmol Vis Sci 2005;46: 514–520.PubMedGoogle Scholar
  105. 105.
    Predictor variable analysis to determine onset of retinal toxicity in children on vigabatrin therapy. Invest Ophthalmol Vis Sci 2005; 46:E-Abstract 611.Google Scholar
  106. 106.
    Kälviäinen R, Nousiainen I. Visual field defects with vigabatrin: epidemiology and therapeutic implications. CNS Drugs 2001;15: 217–230.PubMedGoogle Scholar
  107. 107.
    Committee for Proprietary Medicinal Products (CPMP), European Agency for the Evaluation of Medicinal Products (EMeA). Opinion following an article 12 referral: Vigabatrin. Report no. CPMP/1357/99. November 5, 1999. Available at: http://www. emea.europa.eu/pdfs/human/phv/135799ENB.pdf.Google Scholar
  108. 108.
    Hardus P, Verduin WM, Berendschot TT, et al. The value of electrophysiology results in patients with epilepsy and vigabatrin associated visual field loss. Acta Ophthalmol Scand 2001;79: 169–174.PubMedGoogle Scholar
  109. 109.
    Hardus P, Verduin WM, Engelsman M, et al. Visual field loss associated with vigabatrin: quantification and relation to dosage. Epilepsia 2001;42: 262–267.PubMedGoogle Scholar
  110. 110.
    Benozzi JI, Jaliffa C, Nahum P, et al. Visual alterations in Argentinean patients receiving vigabatrin. Invest Ophthalmol Vis Sci 2001;42(4): S65. Abstract.Google Scholar
  111. 111.
    Newman WD, Tocher K, Acheson JF. Vigabatrin associated visual field loss: risk factors and natural history. Invest Ophthalmol Vis Sci 2001;42(4): S937. Abstract.Google Scholar
  112. 112.
    Kinirons P, Cavalleri GL, O’Rourke D, et al. Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose. Epilepsia 2006;47: 311–317.PubMedGoogle Scholar
  113. 113.
    Vanhatalo S, Nousiainen I, Eriksson K, et al. Visual field constriction in 91 Finnish children treated with vigabatrin. Epilepsia 2002;43: 748–756.PubMedGoogle Scholar
  114. 114.
    Malmgren K, Ben-Menachem E, Frisen L. Vigabatrin visual toxicity: evolution and dose dependence. Epilepsia 2001;42: 609–115.PubMedGoogle Scholar
  115. 115.
    Schmidt T, Ruther K, Jokiel B, Pfeiffer S, Tiel-Wilck K, Schmitz B. Is visual field constriction in epilepsy patients treated with vigabatrin reversible? J Neurol 2002;249: 1066–1071.PubMedGoogle Scholar
  116. 116.
    Steinhoff BJ, Freudenthaler N, Paulus W. The influence of established and new antiepileptic drugs on visual perception. 1. A placebo-controlled, double-blind, single-dose study in healthy volunteers. Epilepsy Res 1997;29: 35–47.PubMedGoogle Scholar
  117. 117.
    Tiel-Wilck K, Jokiel B, Zinser P, et al. Afferent visual function after single dose application of gamma-vinyl-GABA. Neuroophthalmology 1995;15: 305–310. Abstract.Google Scholar
  118. 118.
    Best JL, Acheson JF. The natural history of vigabatrin associated visual field defects in patients electing to continue their medication. Eye 2004;19: 41–44.Google Scholar
  119. 119.
    Newman WD, Tocher K, Acheson JF. Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal. Eye 2002;16: 567–571.PubMedGoogle Scholar
  120. 120.
    Mauguiere F, Chauvel P, Dewailly J, Dousse N; PMS Study Multicenter Group. No effect of long-term vigabatrin treatment on central nervous system conduction in patients with refractory epilepsy: results of a multicenter study of somatosensory and visual evoked potentials. Epilepsia 1997;38: 301–308.PubMedGoogle Scholar
  121. 121.
    American Academy of Ophthalmology. Automated perimetry. Ophthalmology 1996;103: 1144–1151.Google Scholar
  122. 122.
    Westall CA, Panton CM, Levin AV. Time courses for maturation of electroretinogram responses from infancy to adulthood. Doc Ophthalmol 1998;96: 355–379.PubMedGoogle Scholar
  123. 123.
    National Institutes of Health Consensus Conference. Surgery for epilepsy. JAMA 1990;264: 729–733.Google Scholar
  124. 124.
    Brodie MJ, Kwan P. Staged approach to epilepsy management. Neurology 2002;58(8 suppl 5): S2-S8.PubMedGoogle Scholar
  125. 125.
    Meador KJ. Cognitive outcomes and predictive factors in epilepsy. Neurology 2002;58(8 suppl 5): S21-S26.PubMedGoogle Scholar
  126. 126.
    French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs, II: Treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2004;45: 410–423 [Erratum in: Epilepsia 2004;45:1299].PubMedGoogle Scholar
  127. 127.
    Tomson T, Walczak T, Sillanpaa M, Sander JW. Sudden unexpected death in epilepsy: a review of incidence and risk factors. Epilepsia 2005;46(suppl 11): 54–61.PubMedGoogle Scholar
  128. 128.
    Mayer H, Benninger F, Urak L, Plattner B, Geldner J, Feucht M. EKG abnormalities in children and adolescents with symptomatic temporal lobe epilepsy. Neurology 2004;63: 324–328.PubMedGoogle Scholar
  129. 129.
    Kivity S, Lerman P, Ariel R, Danziger Y, Mimouni M, Shinnar S. Long-term cognitive outcomes of a cohort of children with cryptogenic infantile spasms treated with high-dose adrenocorticotropic hormone. Epilepsia 2004;45: 255–262.PubMedGoogle Scholar
  130. 130.
    Guerrini R, Parmeggiani L. Practitioner review: use of antiepileptic drugs in children. J Child Psychol Psychiatry 2006;47: 115–131.PubMedGoogle Scholar
  131. 131.
    Mackay M, Weiss S, Snead OC 3rd. Treatment of infantile spasms: an evidence-based approach. Int Rev Neurobiol 2002;49: 157–184.PubMedGoogle Scholar
  132. 132.
    Van Ness PC. Therapy for the epilepsies. Arch Neurol 2002;59: 732–735.PubMedGoogle Scholar
  133. 133.
    Devinsky O. Patients with refractory seizures. N Engl J Med 1999;340: 1565–1570.PubMedGoogle Scholar
  134. 134.
    Shields WD. Infantile spasms: little seizures, big consequences. Epilepsy Curr 2006;6: 63–69.PubMedGoogle Scholar

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc. 2007

Authors and Affiliations

  • James W. Wheless
    • 1
  • R. Eugene Ramsay
    • 2
  • Stephen D. Collins
    • 3
  1. 1.Le Bonheur Children’s Medical CenterUniversity of Tennessee Health Science CenterMemphis
  2. 2.University of Miami/Jackson Memorial Medical CenterMiami
  3. 3.Ovation PharmaceuticalsDeerfield

Personalised recommendations